The Motley Fool

Will Aurora Cannabis (TSX:ACB) Stock Add to its 30% Gain in 2021?

Image source: Getty Images

Shares of marijuana stocks have experienced a significant uptick in the last three months. Ever since Joe Biden won the presidential race south of the border, investors are optimistic that the Democrats will decriminalize or even legalize marijuana consumption at the federal level.

These developments meant shares of Aurora Cannabis (TSX:ACB)(NYSE:ACB) have returned close to 30% year to date. Despite the recent rally, ACB stock is still trading 93% below its record high.

Aurora Cannabis stock has, in fact, been one the worst performers in the cannabis space, as it continues to grapple with widening losses, lower-than-expected demand, massive inventory write-downs, and significant dilution of shareholder wealth.

Let’s take a look to see if the stock is a good buy right now.

Aurora Cannabis reports Q2 results

Last month, Aurora Cannabis disclosed its fiscal second-quarter-of-fiscal-2021 results and reported sales of $70.3 million. This meant the top line grew 11% year over year in Q2. The company also managed to report an EBITDA loss of $12.1 million, which was lower than its prior-year loss of $53.1 million.

Further, Aurora Cannabis also reduced its cash burn by 74% to $70.5 million in Q2. However, it still recorded impairment charges of $221.6 million, which was attributed to its plant, property, and equipment, as the company focused on downsizing operations in the last few quarters.

ACB is also expected to benefit from a rebound in sales in Canada’s marijuana market after several quarters of oversupply. The company sold 15,253 kg of dried cannabis in Q2 — a significant increase of 61% compared with the prior-year period.

The U.S. market is not looking too good for ACB

While Aurora Cannabis has managed to lower losses and improve its top line in Q2, investors would be worried about the company’s sales south of the border. In May 2020, ACB acquired U.S.-based CBD company Reliva that had a trailing 12-month revenue figure of US$10 million.

However, in the last two quarters, ACB’s CBD segment generated just US$2.7 million in sales. This lack of revenue growth is a surprise, as Reliva’s products are sold in 23,000 stores in North America.

Aurora Cannabis is also losing market share in a high-growth segment and the total addressable market for CBD is valued at $19.6 billion in the U.S.

Another major reason for concern for Aurora investors is the company’s weak balance sheet metrics. ACB ended the December quarter with $565 million in cash. However, it also has close to $500 million in debt and convertible liabilities. The marijuana giant continues to raise equity capital, and, in the last six months, its outstanding shares have risen to 197.39 million, up from 77.39 million.

If it continues to post an EBITDA loss in the upcoming quarters, you should expect a further dilution in shareholder wealth.

The Foolish takeaway

Aurora Cannabis is valued at a price-to-forward-sales multiple of seven, which might not look too steep considering it’s part of a growing industry. However, investing in this stock carries significant risks due to ACB’s negative profit margins, falling market share, and weak financials.

Are you a fan of growth stocks?

Should you invest $1,000 in Aurora Cannabis right now?

Before you consider Aurora Cannabis, you may want to hear this.

Motley Fool Canadian Chief Investment Advisor, Iain Butler, and his Stock Advisor Canada team just revealed what they believe are the 10 best stocks for investors to buy right now... and Aurora Cannabis wasn't one of them.

The online investing service they've run since 2013, Motley Fool Stock Advisor Canada, has beaten the stock market by over 3X. And right now, they think there are 10 stocks that are better buys.

Learn More Today!

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss an important event.

Iain Butler and the Stock Advisor Canada team only publish their new “buy alerts” twice a month, and only to an exclusively small group.

This is your chance to get in early on what could prove to be very special investment advice.

Enter your email address below to get started now, and join the other thousands of Canadians who have already signed up for their chance to get the market-beating advice from Stock Advisor Canada.